# Triamcinolone

## Triamcinolone 10mg/1mL

##### 

| TAH Drug Code      | ITRI1                                                                                                                                                                                                                                                                                                                                                       |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Intra-articular Inflammatory joint disease                                                                                                                                                                                                                                                                                                                  |
| Dosing             | Adult: INS 2.5-40mg or IM 40-60mg per time, could inject 2-3 times if symptoms reappear. Children > 6 years: IM 30-200mcg daily to weekly.                                                                                                                                                                                                                  |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                               |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                               |
| Contraindications  | Untreated systemic fungal, bacterial, viral or parasitic infection, hypersensitivity. Neonates (Parenteral)                                                                                                                                                                                                                                                 |
| Adverse Effects    | HPA axis supression, intracranial hypertension, Cushing's syndrome, growth retardation in children; osteoporosis, fractures. Peptic ulceration; glaucoma; hyperglycaemia; GI upsets; increased appetite; increased fragility of skin; behavioural changes. Topical: Systemic absorption if applied to large areas, broken skin or under occlusive dressing. |
| Pregnancy          | Human (and Animal) Data Suggest Risk                                                                                                                                                                                                                                                                                                                        |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                               |

## 4% Triamcinolone 40mg/1mL

##### 

| TAH Drug Code      | ITRI4                                                                                                                                                                                                                                                                                                                                                       |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Inflammatory skin conditions.                                                                                                                                                                                                                                                                                                                               |
| Dosing             | Adult: INS 2.5-40mg or IM 40-60mg per time, could inject 2-3 times if symptoms reappear. Children > 6 years: IM 30-200mcg daily to weekly.                                                                                                                                                                                                                  |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                               |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                               |
| Contraindications  | Untreated systemic fungal, bacterial, viral or parasitic infection, hypersensitivity. Neonates (Parenteral)                                                                                                                                                                                                                                                 |
| Adverse Effects    | HPA axis supression, intracranial hypertension, Cushing's syndrome, growth retardation in children; osteoporosis, fractures. Peptic ulceration; glaucoma; hyperglycaemia; GI upsets; increased appetite; increased fragility of skin; behavioural changes. Topical: Systemic absorption if applied to large areas, broken skin or under occlusive dressing. |
| Pregnancy          | Human (and Animal) Data Suggest Risk                                                                                                                                                                                                                                                                                                                        |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                               |

